Skip to content

Intraocular Pressure in Children With Acute Lymphoblastic Leukemia (ALL) Treated With High Dose Steroids

Intraocular Pressure in Children With ALL Treated With High Dose Steroids

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04593745
Acronym
ALL
Enrollment
100
Registered
2020-10-20
Start date
2018-07-09
Completion date
2024-07-31
Last updated
2021-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ALL, Childhood, Steroid-Induced Glaucoma

Brief summary

Childhood ALL patients are treated with high dose steroids. The study will follow the intraocular pressure of children treated in according to an AIEOP-BFM protocol, during the induction phase that will be compared to the pressure before treatment. Potential risk factors for developing elevated intraocular pressure will be estimated.

Detailed description

Children with ALL in Israel are treating according to the BFM ALL Protocol which contains high dose steroid therapy. One of the known side effects of high dose steroids is Intraocular hypertension, glaucoma, and even irreversible optic nerve injury. Early diagnosis of elevated intraocular pressure (IOP) and early therapeutic interventions might help to prevent future ocular damage. The purpose of this study is to determine the risk of developing evaluate Intraocular pressure during high dose steroid therapy. If elevated IOP will be common enough, we will try to corelate the risk of elevated IOP with potential risk factors, such as initial IOP, WBC at diagnosis, etc. Intraocular pressure will be measured by ophthalmologists using iCare devise: TONOPEN during general anesthesia at the day of diagnosis of ALL before steroid therapy initiation, and then after 15 and 33 days. Children with elevated IOP will continue ophthalmologists' follow up and treatment as necessary. All parents or patients' guardians will sign informed consent for participating in the study. The study group contains all newly diagnosed children with ALL in Schneider Children Medical Center.

Interventions

DEVICEIntraocular pressure measurment

Intraocular pressure measurmentt using iCare devise: TONOPEN

Sponsors

Rabin Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Months to 20 Years
Healthy volunteers
No

Inclusion criteria

* ALL diagnosis * treated with an AIEOP-BFM protocol (including steroids)

Exclusion criteria

\* Any prior eye condition that can affect intra ocular pressure or its measurement

Design outcomes

Primary

MeasureTime frameDescription
intra-ocular pressure (IOP)15 days of steroid treatmentElevated IOP will be defined as pressure \>21 mmHg; The risk of developing elevated IOP will be correlated with potential risk factors (T ALL vs. B ALL; WBC at diagnosis; initial IOP at diagnosis etc.)

Countries

Israel

Contacts

Primary ContactShlomit Barzilai Birenboim, MD
Bshlomit@clalit.org.il03-9253461

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026